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Abstract The zeta potential of the protein corona around car-
boxyl particles has been measured using tunable resistive
pulse sensing (TRPS). A simple and rapid assay for character-
ising zeta potentials within buffer, serum and plasma is pre-
sented monitoring the change, magnitude and distribution of
proteins on the particle surface. First, we measure the change
in zeta potential of carboxyl-functionalised nanoparticles in
solutions that contain biologically relevant concentrations of
individual proteins, typically constituted in plasma and serum,
and observe a significant difference in distributions and zeta
values between room temperature and 37 °C assays. The effect
is protein dependent, and the largest difference between the
two temperatures is recorded for the γ-globulin protein where
the mean zeta potential changes from −16.7 to −9.0 mV for 25
and 37 °C, respectively. This method is further applied to
monitor particles placed into serum and/or plasma. A
temperature-dependent change is again observed with serum
showing a 4.9 mV difference in zeta potential between sam-
ples incubated at 25 and 37 °C; this shift was larger than that
observed for samples in plasma (0.4 mV). Finally, we monitor
the kinetics of the corona reorientation for particles initially
placed into serum and then adding 5 % (V/V) plasma. The
technology presented offers an interesting insight into protein
corona structure and kinetics of formation measured in bio-
logically relevant solutions, i.e. high protein, high salt levels,
and its particle-by-particle analysis gives a measure of the
distribution of particle zeta potential that may offer a better
understanding of the behaviour of nanoparticles in solution.
Keywords Biosensor . TRPS . Zeta potential . Protein
corona . Tunable pores
Introduction
In recent years, synthesis methods for nanoparticles have
evolved to the extent that particle size, shape and composition
can be easily modified [1–4] and this had led in turn to great
advances in the field of diagnostics [5, 6], drug delivery [7–9]
and technology platforms [10, 11]. With the desire to under-
stand and improve nanomaterials comes a need for character-
isation platforms to offer rapid analysis of size, charge and
shape. Ensemble techniques that take measurements on sev-
eral particles simultaneously and provide an average measure-
ment can underestimate subpopulations within multimodal
samples [12, 13], and a raft of technologies have appeared to
help tackle this [14, 15]. Such technologies now offer an abil-
ity to quantify the population of particles with single particle
resolution building an understanding that not all particles are
created equal and there exists distributions such as particle
size or ligand density.
One such technology is based on the Coulter Counter
principle, referred to as resistive pulse sensing (RPS)
[16–18]. The technique allows the characterisation of proteins,
inorganic ions, colloids and nanoparticles within their natural
environment. Two categories of resistive pulse sensors exist
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that utilise either biological [19, 20] or inorganic nanopores
[21–23]. Here, we describe a recent adaptation to inorganic
pores that uses a tunable elastomeric pore termed tunable re-
sistive pulse sensing (TRPS) [14, 24–36]; the pore can be
stretched in real time to suit the sample. The brief setup and
theory for TRPS technologies is as follows: A stable ionic
current is established by two electrodes, separated by a pore;
as particles/analytes translocate the pore, they temporarily oc-
clude ions, leading to a transient decrease in current known as a
‘blockade event’, examples of which can be seen in Fig. 1. In
the TRPS arrangement used here, the pore is mounted laterally
so that particles typically move from the upper fluid cell into
the lower fluid cell, aided by an inherent pressure head due to
40 μl of liquid in the upper fluid cell of approximately 50 Pa
[35]. By monitoring changes in blockade width, blockade
magnitude (Δip) and blockade frequency (events/min), it is
possible to elucidate the zeta potential, size and concentration
of colloidal dispersions in situ [14, 37, 38]. By controlling the
aspect ratio of the pore, resistive pulse sensors have been used
to measure analytes that range from single molecules, DNA,
proteins, cellular vesicles to cell bacteria and viruses; detailed
reviews on the types of analytes and applications can be found
elsewhere [24, 36, 39, 40]. TRPS is becoming an increasingly
common variation of RPS for the characterisation of biological
and inorganic nanomaterials [24, 36] and since its conception
has been tested against alternative technologies such as DLS/
PALS [14, 15, 41–44], TEM [33], and ultracentrifugation [44]
for the characterisation of nanomaterials [15, 45].
The how and where of measuring the properties of particles
are important to consider as changing pH, ionic strength or
temperature, or purifying particles can give a misrepresenta-
tion of their behaviour in their natural environment. In the case
of nanomaterials that are intended to be used in vivo, it is not
properties within synthesis processes that determine their bio-
logical activity, but how they interact with proteins upon en-
tering the body. Upon the addition of nanoparticles to biolog-
ical fluids, there is an almost immediate fouling of their sur-
faces with proteins, peptides and other cellular apparatus
forming a layer known as the protein corona [46–48]. The
composition of the corona has been shown to determine the
eventual properties of the particles [49–51] and has been re-
ported as critically affecting pathophysiological effects of
nanoparticles [52]. The structure of the protein corona can
be dynamic and complex and is different for particles of the
same composition but with different surface chemistries and
size in the same solution [46, 53]. Detailed studies of the
corona have been performed using an array of technologies
including mass spectroscopy [54, 55]. Various techniques
have been used to look at a range of specificities of protein
coronas, for example, protein corona thickness has been in-
vestigated using ensemble techniques such as dynamic light
scattering (DLS) and differential centrifugal sedimentation
Fig. 1 Particles in the presence of
human plasma and serum
showing the formation of both a
‘hard’ and ‘soft’ protein corona.
I1.0, I0.8, I0.6, I0.4, I0.2 represent the
position of the particle as it
translocates the pore (where I1.0 is
the narrow pore entrance) and are
relative to T1.0, T0.8, T0.6, T0.4,
T0.2, which represent the time
taken (ms) for the particle to reach
that position. T1.0, is equivalent to
dRmax when the blockade event is
at 100 % magnitude; T0.8, T0.6,
T0.4, T0.2, correspond to when the
blockade is 80, 60, 40, and 20 %
of its dRmax and indicates the
particle traversing the pore
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(DCS) [49, 56]. Protein corona conformation has been studied
using circular dichroism (CD) and fluorescence quenching [57,
58]; the affinity has also been a popular characterisation pro-
perty of protein coronas and has previously been measured
using size exclusion chromatography (SEC), surface plasmon
resonance (SPR) and isothermal calorimetry (ITC) [49, 56,
59]. A frequent and easy value used to characterise the corona
is zeta potential [46, 48, 50, 54, 60]. The zeta potential repre-
sents the value of the electrostatic potential at the plane of
shear, and typically for nanoparticle systems, zeta potential
values of ±30 mVare representative of stabilised particles [61].
When nanoparticles are introduced to biological fluids, the
protein corona is formed in a series of layers, otherwise known
as the ‘hard’ and ‘soft’ corona. Proteins forming the hard
corona are those with a higher affinity that interact directly
with the nanoparticle surfaces, whereas proteins forming the
soft corona are those engaging in weaker protein–protein in-
teractions with the hard corona [56, 62]. It has previously been
found that a vast range of particles bind successfully to apoli-
poproteins in physiological fluids [55]. Formation of a protein
corona alters the size, aggregation properties and surface
properties of nanoparticles [63], thus creating a new biological
distinctiveness for further application. There are 5 main com-
ponents that define the composition of a protein corona: thick-
ness and density, identity and quantity, orientation, conforma-
tion and affinities [63].
Protein adsorption kinetics play a prominent role in this
study and are key to understanding the binding mechanisms
that will occur in a natural environment. Although this process
is time-dependent, the kinetics rely on kon and koff parameters,
indicating the rate constants for adsorption and desorption of
proteins. kon is largely dependent on how often the protein
contacts the nanoparticle surface, as well as the probability
of successful binding between the two materials [64]. The
strength of the protein–nanoparticle interaction defines koff
[64], and a strong, high-energy interaction will exert a low koff
value. Understanding the kinetics of formation and protein
corona composition is important to understand processes
nanoparticles may undertake when introduced into the body
and into physiological conditions.
Here, we present a protocol for the rapid analysis of the
corona zeta potential and demonstrate its versatility bymaking
the measurement in solutions that mimic the natural environ-
ment, i.e. high ionic strength and high protein composition.
By making comparable measurements of carboxyl polysty-
rene nanoparticles in a range of incubation temperatures and
with different proteins, a clear difference in magnitude and
variation of zeta potential within the particle population was
observed; the three proteins chosen to demonstrate this are the
most predominant (in terms of quantity) proteins in normal
human plasma and we perform the experiment concentrations
that would reflect normal plasma. The ability to have individ-
ual particle resolution provides an opportunity to see the full
variation of zeta potential in a single sample. The findings
highlight the need to monitor the protein corona and its for-
mation at biologically relevant temperatures and suggest that
the kinetics of protein adsorption and spread in zeta potential
values varies for each of the proteins and biological mediums
studied. Finally, we show the scope of the technology by
monitoring the change in the hard and soft corona elements
interacting with the particles through incubation in serum,
followed by the addition of a small amount (5 % (V/V)) of
plasma. It is known that protein components of a higher con-
centration or affinity to the particle can remove and restructure
the soft corona that is formed in biological fluid [55], and we
monitor the rate of this change and the kinetic effects that
eventually settle on a new zeta potential value.
Materials and methods
Chemicals and reagents
The initial buffer used for particle analysis was phosphate
buffered saline (1× PBS tablet (0.01 M phosphate buffer,
0.0027 M potassium chloride, 0.137 M sodium chloride) in
200 mL deionised water (18.2 MΩ cm)). PBS tablets (P4417)
were purchased from Sigma-Aldrich, UK.
Carboxyl polystyrene standards
Carboxylated polystyrene particles, denoted as CPC200, with a
mean nominal diameter of 210 nm and stock concentration of
1 × 1012 particles/mL, were purchased fromBangs Laboratories,
USA and used as a calibrant for zeta potential analysis, as well
as the sample particles. CPC200s were vortexed for 30 s follow-
ed by a 2 min sonication to ensure monodispersity prior to any
TRPS analysis or sample incubation.
Isolated proteins
All isolated proteins studied were purchased from Sigma-
Aldrich, UK, without modification or purification unless stat-
ed otherwise: fibrinogen from human plasma (F3879), albu-
min from human serum (A9511) and γ-globulin from human
blood (G4386).
Human plasma and serum samples
Blood samples were collected and prepared at Peterborough
City Hospital Pathology Laboratory, UK. Plasma collection
was completed using blood from a healthy volunteer donor
that was collected in citrate medium (Sarstedt, UK.) and cen-
trifuged at 3000 rpm for 8 min. Serum was gathered using
blood from a healthy volunteer donor that was collected into
a Sarstedt monovette/collection tube, and was centrifuged at
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3000 rpm for 6 min. The supernatants from each sample were
transferred into separate sample vials and stored at room tem-
perature prior to use.
Isolated protein studies
Using PBS buffer, isolated albumin, fibrinogen and γ-
globulin samples were prepared to give the following concen-
trations: 43, 3.2 and 20 g/L, respectively, as to mimic protein
concentrations found in human blood. The concentrations of
proteins were measured from human plasma and serum sam-
ples. The samples used in this study were analysed by an
Instrument Laboratory ACL TOP CTS500 coagulation
analyser (Werfen, Spain) to obtain the fibrinogen concentra-
tion. Albumin and immunoglobulin levels were taken from
test serum samples that were analysed by a Roche Cobas
Biochemistry Analyser (Roche Diagnostics, Switzerland).
CPC200s were added resulting in a final concentration of
1 × 1010 particles/mL. Each sample was vortexed for 30 s
and sonicated for 1 min before incubation. Samples were then
incubated at 25 and 37 °C in a mini dry bath (Benchmark
Scientific, USA) for 10 min prior to TRPS analysis.
Serum and plasma studies
Human plasma and serum were prepared immediately before
the experiments to minimise ex vivo artefactual changes. The
prepared plasma and serum were separately diluted 10-fold
with PBS before CPC200s were added to both samples
resulting in a final particle concentration of 1 × 1010 parti-
cles/mL, herein these solutions are referred to as serum and
plasma. Samples were vortexed for 30 s and sonicated for
1 min, followed by incubation in a mini dry bath
(Benchmark Scientific, USA) at 25 and 37 °C for 10 min
before being removed for TRPS analysis. It should be noted
that it is possible for some proteins in human plasma and
serum to interact and adsorb onto the pore walls; therefore, a
control measurement of CPC200s in PBS (of known zeta po-
tential, -20 mV) was completed before and after each protein/
plasma/serum sample to establish if any changes had occurred
to the pore itself.
Plasma spiking assay
Human serum was 10× diluted in PBS before CPC200s were
added to a final concentration of 1 × 1010 particles/mL.
Samples were vortexed for 30 s and sonicated for 1 min before
being incubated for 10 min at 25 and 37 °C in a mini dry bath
(Benchmark Scientific, USA). At 10 min, 5 % (V/V) human
plasma was added to the serum samples and the samples were
vortexed for 30 s. TRPS measurements were completed once
the plasma had incubated with the serum sample for 5, 10, 15,
20, 30 and 60 min.
Tunable resistive pulse sensing
All measurements were completed using the qNano (Izon
Science Ltd, NZ). The system utilises tunable nanopores with
propriety data capturing software (Izon Control Suite
v3.1.2.53). In all experiments, the lower fluid cell contained
80μL of PBS buffer, ensuring no bubbles were present.When
a sample measurement was being taken, the upper fluid cell
contained 40 μL of the sample (suspended in PBS buffer).
After each measurement was taken, the nanopore was washed
several times by removing and replacing 40 μL of buffer, each
time applying varied pressures until no particles were ob-
served. This was performed several times to remove any re-
sidual particles in the system and thus ensure no cross-
contamination between samples. The nanopores used
throughout all experiments were capable of detecting particles
within the size range of 100–300 nm (as stated by the manu-
facturer, Izon Science Ltd) and denoted as an NP200. To ac-
count for the variation in the manufacturing of the nanopores,
appropriate stretch (44–46 mm), voltage and pressure were
applied in all experiments; the conditions were matched as
to the blockade magnitudes of CPC200s in PBS being of a
similar size throughout all experiments. All samples were
vortexed for 30 s and sonicated for 2 min prior to analysis.
Zeta potential measurements using TRPS
When carrying out zeta potential measurements, the nanopore
stretch was kept the same for a particular dataset and nanopore
between calibration and sample measurements. To calibrate a
nanopore for zeta potential analysis, the calibration particles,
of known size and zeta potential, were measured in PBS at 3
applied voltages; the particles measured at the highest voltage
were measured at 2 external pressures (in addition to the in-
herent 47 Pa pressure head on the system). When running the
samples, the blockade magnitudes were ensured to be at least
100× larger than the respective background noise of ca. 10 pA.
In accordance with the calibration runs, the samples were run
at the highest calibration voltage. Calibration measurements
were completed when a new nanopore (NP200) was intro-
duced to ensure conditions were matched so the blockade
magnitudes of CPC200s in PBS were of a similar size to other
NP200s used for this study. A CPC200 sample in PBSwas run
after each protein/plasma/serum sample to ensure the zeta po-
tential of the pore remained unchanged and as such did not
affect the measured zeta potential of further samples.
Results and discussion
Zeta potential values were determined from the particle veloc-
ities as they traversed the nanopore; a full description of the
protocol and theory can be found elsewhere [21, 38]. Briefly,
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the duration of particle translocation is measured as a function
of applied voltage, taking an average electric field and average
particle velocities over the entire sensing zone that is a regular
conical pore. Each particle’s electrophoretic mobility is de-
rived from 1/T, where T is the blockade duration and voltage,
multiplied by the square of the sensing zone length, L, as part
of a calibration constant. Figure 1 shows the conical sensing
zone and an example of the blockade duration times, T, as a
result of a blockade event at various positions, I, in the
nanopore. T1.0 for example is equivalent to when the blockade
is 100 % in magnitude and is indicative of I1.0, the position to
which the particle is approaching the pore entrance. T0.6 re-
lates to position I0.6 where the blockade is 60 % in magnitude
and the particle has traversed 40 % of the pore. It is important
to note each blockade depicted in the signal trace is indicative
of a single particle as it passes through the pore, highlighting
the advantages of using particle-by-particle technologies such
as TRPS.
Average velocities determined across multiple reference
points within the nanopore vastly reduce any errors in this zeta
potential calculation process [38]. The calibration of the pore
itself is based on a linear relationship between 1/Tand voltage,
V, at each blockade reference point. Equation 1 shows the
direct relationship between particle velocities and their zeta
potentials, vxð Þel Cal and vix
 
el Sample are the particle velocities
of calibration and sample particles, respectively, and ξnet Cal
and ξix net Sample represent their zeta potential values [38].
vix
 
el Sample
vxð Þel Cal
¼ ξ
i
x net Sample
ξnet Cal
ð1Þ
Equation 2 shows the zeta potentials measured at each of
the blockade reference points can then be used to determine
the zeta potential of each individual particle, i, as it passes
through the pore, ξiSample.
ξiSample ¼
∑xξ
i
x Sample
∑x
¼
∑x vix Sample−vPx Cal  P
 .
vVx Cal  V
 
∑x
 ξnet Cal þ ξm ð2Þ
Where vVx Cal,v
P
xCal, P and V are electrokinetic velocity per
unit voltage, convective velocity per unit pressure, applied
pressure and voltage, respectively. Ix is the position of the
particle in the nanopore after time t = Tx, vx Sample
i is the sum
of the particle velocities at relative positions, lx [38].
The proteins used in this study were chosen based on their
relative abundances in both blood plasma and serum samples.
Albumin and γ-globulin are present in both plasma and serum
samples at approximately 4 and 2 %, whereas fibrinogen (as
well as other clotting factors) is only found in plasma at ap-
proximately 0.4 %. Zeta potential values measured for parti-
cles incubated with each of the isolated proteins are shown in
Fig. 2 (for reference the starting zeta potential of a CPC200 in
PBS is −20 mV).
When the particles were incubatedwith each of the proteins
separately at 25 °C, both fibrinogen and γ-globulin showed a
relatively small change inmean zeta potential from particles in
PBS buffer, differences of 3.2 and 3.6 mV, respectively. The
size and zeta potential distributions of CPC200 carboxyl par-
ticles in PBS are shown in Fig. 3. Albumin was seen to have a
much larger effect on the particle zeta potentials at 25 °C as the
zeta values were reduced by 9.2 mV from the PBS control.
Albumin was at the highest concentration at 40 g/L in com-
parison to the fibrinogen and γ-globulin samples only having
protein concentrations of 4 and 20 g/L respectively. The pro-
tein concentrations were chosen to replicate the typical com-
position usually found in the human body, although it should
be noted that the concentration of proteins to that of the par-
ticles in each experiment was always in a large excess as to
coat each surface of every particle. The proteins were also
investigated at a constant concentration (5 g/L) at a 25 °C
incubation temperature for 10 min to determine whether pro-
tein concentration had an effect on the protein corona on the
particles, results of which are shown in the Electronic
Supplementary Material (ESM), Fig. S1. From this, it was
found that the relative change in zeta potential (from a control
of the particles just in PBS) was smallest for fibrinogen and γ-
globulin with values of 4.3 and 4.9 mV, respectively. The
largest change in zeta potential was again observed for the
albumin protein with a difference of 8.9 mV. These compara-
ble changes show the results are protein specific and not re-
lated to the concentration at these levels. It was therefore ex-
pected that the proteins would adsorb onto the particle surface,
forming the protein corona. Any such protein corona would
change the surface charge density on the particles and be mea-
sured by a change in particle velocity, which in turn is plotted
as the zeta potential. At 25 °C, the small zeta potential changes
for fibrinogen and γ-globulin samples are more than likely
because of the protein isoelectric points and their behaviour
at physiological pH. Albumin has an isoelectric point of 4.7
whereas fibrinogen and γ-globulin have isolectric points of
5.8 and 6.6, respectively [65]. Previous reports have found
that as the adsorption pH moves away from the protein
isolectric points, the adsorbed molecules will occupy a larger
area of the surface. This is due to internal electrostatic repul-
sions and thus a lower structural stability [66]. Our samples
were all suspended in PBS buffer at pH 7.4, and therefore, the
albumin is expected to occupy the largest area of the nanopar-
ticle surface as the adsorption is occurring at a pH furthest
from its isoelectric point. This may be the reason the albumin
shows the largest change in zeta potential after a 25 °C
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incubation in comparison to the smaller changes observed for
fibrinogen and γ-globulin (isoelectric points closer to 7.4).
Particles were also incubated with each of the proteins at a
higher temperature of 37 °C; it was hypothesised that as the
proteins are present in such a large excess that the incubation
time of 10 min would be enough to coat the particles with a
monolayer of protein, and that the temperature would have
little effect on the result. In contrast, at 37 °C, there were
significant differences from values at 25 °C and each protein
produced varying shifts in zeta potential values. At the elevat-
ed temperature, γ-globulin was seen to have the largest reduc-
tion in zeta potential from a value of −20.3 mV (particles in
PBS) to −9.0 mV. This is of particular interest as these results
indicate each protein interacts with the particle surface unique-
ly, having direct implications on the particle zeta potential. γ-
Globulin also showed the largest change in zeta potential as a
function of incubation temperature between 25 and 37 °C
(5.0 mV), whereas albumin showed the smallest change
(1.3 mV). The distribution of zeta potentials for each isolated
protein at 25 and at 37 °C are shown in the ESM, Fig. S2.
The particle-by-particle nature of TRPS allows for individ-
ual particles to be analysed, as well providing a measure of the
spread in values across the sample population. Figure 3 de-
picts the zeta potential versus particle size plots for the given
sample populations summarised in Fig. 2. Note here that each
data point in Fig. 3 is representative of a single particle.
Whilst the distribution of the values does not change as the
incubation temperature increases, the shift in mean zeta poten-
tial as the incubation temperature was significant. This shift
may be due to the affinities of the proteins for the particle
surface being affected by the incubation temperature.
Previous studies have found that negative particles have
Fig. 2 Mean zeta potential (mV) versus the protein the particles were
incubated with. The blue bars show results for a 10-min particle incuba-
tion at 25 °C and the red bars show the mean zeta potential values for
particles incubated with the proteins for 10 min at 37 °C. The green lines
represent the measured mean zeta potential for calibration particles of
known zeta potential (−20 mV) in PBS that were run after each protein
sample to show the protein samples were not having a direct effect on the
pore walls themselves that may influence the recorded zeta potentials of
future samples run on the same pore. Error bars are representative of the
st.dev where n = 3
Fig. 3 Zeta potential (mV) versus particle size (nm). The red, blue and
green datasets are zeta potential distributions for CPC200s incubated for
10min with fibrinogen, γ-globulin and albumin, respectively at (a) 25 °C
and (b) 37 °C. The black data points represent CPC200s in PBS for both
figure parts a and b
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maximum protein adsorption at 15, 35 and 37 °C [67] and
explain why the CPC200s incubated at 37 °C in each protein
medium shifted to a smaller zeta potential value more so than
those incubated at 25 °C. When proteins have a higher affinity
to the particle surface, there is either the formation of a robust
hard corona, or slower release of the proteins from the surface
once absorbed. The hard corona layer will alter the particle
surface chemistry and will result in a slower particle transloca-
tion velocity through the pore due to shielding of the negative
particle surface, which consequently results in a smaller zeta
potential value. Interestingly, at the 25 °C incubation (Fig. 3a),
the γ-globulin and particularly the fibrinogen sample showed a
wider spread of data than those samples incubated at 37 °C
(Fig. 3b). Figure 3b also shows that at elevated temperatures, a
thicker protein corona layer is formed resulting in an increase
in particle size. These results suggest the protein binding kinet-
ics may differ as a function of temperature. The population
spread may be wider at lower temperatures as the proteins
may not have reached maximum levels of adsorption to the
particle surface at 25 °C [67], also supporting the small chang-
es in mean zeta potential at 25 °C demonstrated in Fig. 2.
Monitoring individual protein–nanoparticle interactions is
interesting but becomes more complex in a medium containing
a protein mixture, such as plasma or serum. Both plasma and
serum are extracted from blood samples but contain a different
composition of proteins. Relevant to this study, serum contains
albumin, γ-globulin and apolipoproteins. Plasma has a similar
protein composition to serum, but also contains clotting factors
such as fibrinogen. Figure 4 shows the measured zeta poten-
tials of CPC200s in PBS and of CPC200s incubated in plasma
and serum for 10 min at both 25 and 37 °C.
As seen in the isolated fibrinogen and γ-globulin samples
above, only small changes in zeta values were observed for
both plasma and serum at 25 °C. Interestingly, at the elevated
incubation temperature of 37 °C, the plasma still did not ap-
pear to show a significant difference in zeta potential, whereas
the sample in serum showed a reduction in zeta potential of
5.9 mV. The most prominent difference between plasma and
serum is the presence of clotting factors in plasma; this will
have an inherent effect on the protein corona structure and
resulting interactions with the particle surface [63]. Protein
corona formation is complex in physiological environments
Fig. 4 (a) Mean zeta potential
(mV) versus incubation medium.
Comparison of CPC200 particles
incubated in PBS (green), plasma
and serum for 10 min at 25 °C
(blue) and 37 °C (red). Error bars
are representative of the st.dev
where n = 3. (b) Frequency (%)
versus zeta potential (mV). Zeta
potential distributions for
CPC200s incubated for 10 min at
37 °C in plasma (purple) and
serum (pink). Repeat datasets for
CPC200s incubated in both
plasma and serum at 37 °C for
10 min are illustrated in ESM
Fig. S3 and are compared to a zeta
potential distribution of CPC200s
in PBS only
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as it consists of the simultaneous binding of numerous pro-
teins to the particle surface creating both protein-nanoparticle
interactions as well as protein–protein interactions [63].
Proteins within plasma and serum are undergoing a com-
petitive binding assay to the particle’s surface, and proteins of
higher concentration and/or affinity will bind to the particle
surface more rapidly at the first instance. Protein–protein in-
teractions are also common in plasma and serum samples, and
some proteins will have a higher affinity to a subsequent pro-
tein over the particle surface. Zeta potential distribution as a
function of temperature for the particles incubated with plas-
ma and serum samples are shown in Fig. 5.
When the incubation temperature was increased, the zeta
potential for both particles in plasma and serum were smaller.
The advantage of distribution studies of a sample population is
the discrete differences that can be identified, that cannot be
determined immediately from mean values. For example, in
Fig. 5a, the distribution shape of the particles incubated with
plasma at 25 °C (red) is almost twice as wide as the distribution
for 37 °C (purple), yet themean values only changed by 0.4mV
between temperatures, a negligible difference. The difference in
distribution shape can be reflected using median skewness
values. The median skewness values for a given sample popu-
lation of particles incubated in plasma were 0.111 and −0.065
for incubation temperatures of 25 and 37 °C, respectively.
Particles in serum showed the same effect and as the incubation
temperature was increased, the median skewness values de-
creased from −0.105 (25 °C) to −0.343 (37 °C).
The protein–nanoparticle interactions in plasma and serum
were evidently varied, and to investigate this further, we com-
pleted a plasma spiking experiment. This aimed to ascertain if
the soft corona formed in the plasma would reorganise in the
presence of serum proteins. Figure 6 shows the effect on zeta
potential as plasma (5 % V/V) was used to spike samples con-
taining nanoparticles in serum at various time intervals.
Plasma protein adsorption onto a particle surface is due to
the Vroman effect and is defined as the constant change in
protein composition based on continuous adsorption and de-
sorption at an interface [68]. There can be both faster and
slower stages in this effect dependent on the protein. For ex-
ample, albumin, γ-globulin and fibrinogen are all proteins that
will adsorb rapidly onto a surface based on their high
Fig. 5 (a) Zeta potential
distributions for CPC200s
incubated in plasma for 10 min at
25 °C (red) and 37 °C (purple).
(b) Zeta potential distributions for
CPC200s incubated in serum for
10min at 25 °C (green) and 37 °C
(blue)
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abundances, but are generally replaced by apolipoproteins in a
matter of seconds [69] due to their fast dissociation properties.
Apolipoproteins, however, although of low abundance, have a
much slower dissociation constant and will therefore remain
on the potential surface for longer [70]. As with a lot of
nanoparticle-based assays, there may be an element of com-
petition between proteins in binding to the nanoparticle sur-
face that will affect the protein corona structure as displace-
ment and exchange reactions may then take place over time.
As the hard corona involves the higher affinitive proteins, this
should remain adsorbed onto the nanoparticle surface over
time and during any biophysical event that may occur [63].
The soft corona involves much weaker protein interactions in
the system and will therefore dissociate more rapidly and pro-
tein exchange will occur much more readily. This effect is
dependent on the relative protein concentrations of all proteins
present in the plasma and serum samples. It is well known that
protein concentration has a significant effect on the formation
of a protein corona when incubated with nanoparticles [55,
71]; when a protein is of high concentration in a given sample,
that protein will initially occupy the nanoparticle surface and
form a protein corona [55] at a potentially faster rate than
those of lower concentrations that may be later exchanged
for those at a lower concentration but higher affinity. This
effect also depends on the nanomaterial and there have been
cases where proteins that have adsorbed first have had the
longest residence time [72].
The first measurement was taken after the plasma had been
introduced to the serum sample for 5 min. Between 5 and
10 min of the plasma being present (Fig. 6(i-ii)), the zeta
potential of the particles was reduced. This is due to the addi-
tion of proteins into the sample, a higher concentration of
proteins interacting with the particles will result in a slower
pore translocation velocity, hence the reduced zeta potential.
Figure 6(iii) shows that after 15 min, the zeta potential was
reduced to its lowest measured value in this experiment. This
is due to some of the plasma proteins displacing those from
serum that may have reversibly bound to the particle surface
as part of a hard corona layer. The plasma proteins may have
been of a higher affinity to those present in the serum sample
and therefore form the new hard corona layer [56, 62]. After
20min and gradually onto 60min (Fig. 6(iv)), the particle zeta
potentials became more negative, indicating an increase in
particle translocation velocity through the pore. We attribute
Fig. 6 The effect of spiking a sample of CPC200s incubated in serum
with plasma. (a) Visual representation of the effect of protein
displacement and exchange within a protein corona system. (i) Protein
corona formed by particle incubation in serum, (ii) introduction of plasma
proteins to sample, (iii) displacement of hard corona proteins due to
proteins of higher affinities and exchange of soft corona proteins, (iv)
Depletion of soft corona layer as proteins dissociate from loose protein-
protein interaction. (b) Particles were incubated in serum for 10 min and
then spiked with 5% (v/v) plasma. Zeta potentials were measured at 5, 10,
15, 20, 30 and 60min. (i)–(iv) indicate the shift in zeta potential as a result
of the effects described in (a)
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this result to the weak interactions of the soft corona layers.
For example, once the plasma proteins have potentially
displaced those in the original hard corona, the displaced pro-
teins will form part of the soft corona and be part of weaker
protein–protein interactions. Over time, the soft corona pro-
teins will dissociate more readily away from the particle due to
their loose interactions [73], reducing the protein coverage
around the particle and thus resulting in a larger zeta potential.
The zeta potential becomes larger after this process as there are
less bound proteins surrounding the particle to reduce the par-
ticle’s translocation velocity. The faster the particle can traverse
the pore, the larger the zeta potential value. This is of particular
interest as it gathers valuable information on how the different
compositions of plasma and serum proteins in a blood sample
would affect a nanoparticle and how they behave differently
when isolated and in a mixture.
Conclusions
We have demonstrated the effects of more prominent pro-
teins found in protein coronas individually (isolated in
PBS) and within their natural environment (within plasma
and serum samples) on carboxylated polystyrene nanopar-
ticle surfaces. Protein–nanoparticle interactions involved
in the formation of a protein corona have been found to
be protein dependent at 25 °C, as well as temperature de-
pendent for each studied protein. Significant changes in
particle zeta potentials were observed when all of the pro-
teins interacted with the nanoparticles at 37 °C. TRPS tech-
nology has enabled the provision of single particle analy-
sis, as well as information on the zeta potential distribu-
tions amongst a given sample population in all experiments
carried out, a more detailed insight than some other previ-
ously used ensemble techniques. We have found that al-
though a stable hard and soft corona can be formed around
particles in serum, we can also track various protein dis-
placement and exchange processes occurring when plasma
proteins are introduced to these samples. This has provided
more detailed information on the affinities and reaction
kinetics of protein coronas dependent on their biological
medium and incubation conditions. A further understand-
ing of protein–nanoparticle interactions in complex matri-
ces and in physiological conditions is proving useful for
advances in biotechnological assays and therapeutics.
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